LENZ Therapeutics (Nasdaq: LENZ), a pharmaceutical company focused on commercializing VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved aceclidine-based eye drop for presbyopia in adults, will host a webcast on Tuesday, August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and discuss recent corporate highlights.
Investors can join via telephone at (800) 715-9871 (Domestic) or (646) 307-1963 (International) using access code 2922111, or via live webcast on the LENZ Therapeutics website in the Investors & Media section. A replay will be available online for 30 days.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
LENZ's prior earnings report, news_id 1055210, was followed by -20.82% in 24 hours, adding a company...
Analysis
LENZ's prior earnings report, news_id 1055210, was followed by -20.82% in 24 hours, adding a company-specific precedent to this scheduling notice. The key watchpoint is the reported financial results; high short positioning remained a risk.
Key Figures
Product concentration:1.44%Webcast date:August 11, 2026Webcast time:4:30 p.m. EDT+1 more
Announced webcast for Q4 and full-year 2025 results
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
The one tag-matched earnings-date announcement was followed by a 6.47% 24-hour gain.
Key Terms
presbyopia, aceclidine, ophthalmologic solution
3 terms
presbyopiamedical
"the treatment of presbyopia in adults"
Presbyopia is the gradual loss of the eye’s ability to focus on close objects as the lens stiffens with age, causing tasks like reading or using a phone to require holding things farther away or using glasses. It matters to investors because it drives steady demand for corrective products and treatments—such as reading glasses, contact lenses, surgical procedures and emerging drugs—much like an aging population consistently needs new or replacement consumer goods and services.
aceclidinemedical
"the first and only FDA-approved aceclidine-based eye drop"
Aceclidine is a medication that activates certain receptors in the eye to tighten the pupil and help open fluid drainage channels, which lowers pressure inside the eye and is used to treat glaucoma. Think of it as a tiny valve adjustment that helps fluid flow out more easily. For investors, developments around aceclidine—such as clinical trial results, regulatory approvals, or licensing—can affect the value and prospects of companies working on eye-care treatments.
A sterile liquid formulation intended for application to the eye—commonly delivered as drops, rinses, or irrigations—to treat, prevent, lubricate, or help diagnose eye conditions. Like windshield washer fluid for a car’s windshield, an ophthalmologic solution must meet strict purity, preservative and packaging standards and often faces specific regulatory pathways and reimbursement rules, factors that affect manufacturing complexity, time to market, and potential sales for investors.
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Tuesday, August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and recent corporate highlights.
To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 2922111. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About LENZ Therapeutics LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com.
Contacts: Dan Chevallard LENZ Therapeutics IR@LENZ-Tx.com
FAQ
When will LENZ Therapeutics (NASDAQ: LENZ) report its Q2 2026 financial results?
LENZ Therapeutics will report its Q2 2026 financial results on Tuesday, August 11, 2026, at 4:30 p.m. EDT. According to LENZ Therapeutics, the update will be provided via a webcast and accompanying conference call.
How can investors access the LENZ Therapeutics Q2 2026 earnings webcast on August 11, 2026?
Investors can access the LENZ Q2 2026 webcast live through the company’s website in the Investors & Media section. According to LENZ Therapeutics, an online replay of the webcast will remain available for 30 days following the event.
What are the dial-in numbers and access code for the LENZ (LENZ) Q2 2026 earnings call?
The domestic dial-in for the LENZ Q2 2026 call is (800) 715-9871 and international is (646) 307-1963. According to LENZ Therapeutics, participants must enter conference access code 2922111 to join the call.
Will a replay be available for the LENZ Therapeutics Q2 2026 financial results webcast?
Yes, a replay of the LENZ Q2 2026 webcast will be available on the company’s website for 30 days. According to LENZ Therapeutics, investors can access it in the Investors & Media section after the live event.
What product focus will be highlighted by LENZ Therapeutics (LENZ) during its Q2 2026 update?
LENZ Therapeutics is focused on commercializing VIZZ® (aceclidine ophthalmologic solution) 1.44% for presbyopia in adults. According to LENZ Therapeutics, VIZZ is described as the first FDA-approved aceclidine-based eye drop for this indication.
Where can shareholders find the LENZ Therapeutics Q2 2026 webcast link and investor information?
Shareholders can find the Q2 2026 webcast link on the LENZ Therapeutics website under Investors & Media. According to LENZ Therapeutics, both the live webcast and 30-day replay will be hosted on this investor-focused section.
